156 related articles for article (PubMed ID: 38683495)
1. ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study.
Maris M; Salles G; Kim WS; Kim TM; Lyons RM; Arellano M; Karmali R; Schiller G; Cull E; Abboud CN; Batlevi C; Kagiampakis I; Rebelatto MC; Lee Y; Kirby LC; Wang F; Bothos J; Townsley DM; Fathi AT; Ribrag V
Target Oncol; 2024 May; 19(3):321-332. PubMed ID: 38683495
[TBL] [Abstract][Full Text] [Related]
2. Preclinical radiolabeling, in vivo biodistribution and positron emission tomography of a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2.
Wichmann CW; Burvenich IJG; Guo N; Rigopoulos A; McDonald A; Cao D; O'Keefe GJ; Gong SJ; Gan HK; Scott FE; Pore N; Coats S; Scott AM
Nucl Med Biol; 2023; 122-123():108366. PubMed ID: 37473513
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
4. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.
Phillips T; Barr PM; Park SI; Kolibaba K; Caimi PF; Chhabra S; Kingsley EC; Boyd T; Chen R; Carret AS; Gartner EM; Li H; Yu C; Smith DC
Invest New Drugs; 2019 Apr; 37(2):297-306. PubMed ID: 30132271
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study.
Stathis A; Flinn IW; Madan S; Maddocks K; Freedman A; Weitman S; Zucca E; Munteanu MC; Lia Palomba M
Invest New Drugs; 2018 Oct; 36(5):869-876. PubMed ID: 29453628
[TBL] [Abstract][Full Text] [Related]
7. Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.
Goldberg AD; Atallah E; Rizzieri D; Walter RB; Chung KY; Spira A; Stock W; Tallman MS; Cruz HG; Boni J; Havenith KEG; Chao G; Feingold JM; Wuerthner J; Solh M
Leuk Res; 2020 Aug; 95():106385. PubMed ID: 32521310
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
[TBL] [Abstract][Full Text] [Related]
9. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.
Daver NG; Montesinos P; DeAngelo DJ; Wang ES; Papadantonakis N; Todisco E; Sweet KL; Pemmaraju N; Lane AA; Torres-Miñana L; Thompson JE; Konopleva MY; Sloss CM; Watkins K; Bedse G; Du Y; Malcolm KE; Zweidler-McKay PA; Kantarjian HM
Lancet Oncol; 2024 Mar; 25(3):388-399. PubMed ID: 38423051
[TBL] [Abstract][Full Text] [Related]
10. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.
Tilly H; Morschhauser F; Bartlett NL; Mehta A; Salles G; Haioun C; Munoz J; Chen AI; Kolibaba K; Lu D; Yan M; Penuel E; Hirata J; Lee C; Sharman JP
Lancet Oncol; 2019 Jul; 20(7):998-1010. PubMed ID: 31101489
[TBL] [Abstract][Full Text] [Related]
11. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies.
Fanale MA; Forero-Torres A; Rosenblatt JD; Advani RH; Franklin AR; Kennedy DA; Han TH; Sievers EL; Bartlett NL
Clin Cancer Res; 2012 Jan; 18(1):248-55. PubMed ID: 22080439
[TBL] [Abstract][Full Text] [Related]
12. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
[TBL] [Abstract][Full Text] [Related]
13. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
Hamadani M; Radford J; Carlo-Stella C; Caimi PF; Reid E; O'Connor OA; Feingold JM; Ardeshna KM; Townsend W; Solh M; Heffner LT; Ungar D; Wang L; Boni J; Havenith K; Qin Y; Kahl BS
Blood; 2021 May; 137(19):2634-2645. PubMed ID: 33211842
[TBL] [Abstract][Full Text] [Related]
14. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC
Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955
[TBL] [Abstract][Full Text] [Related]
15. Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Abrisqueta P; González-Barca E; Panizo C; Pérez JMA; Miall F; Bastos-Oreiro M; Triguero A; Banerjee L; McMillan A; Seymour E; Hirata J; de Guzman J; Sharma S; Jin HY; Musick L; Diefenbach C
Lancet Haematol; 2024 Feb; 11(2):e136-e146. PubMed ID: 38190832
[TBL] [Abstract][Full Text] [Related]
16. Multiplex Bioanalytical Methods for Comprehensive Characterization and Quantification of the Unique Complementarity-Determining-Region Deamidation of MEDI7247, an Anti-ASCT2 Pyrrolobenzodiazepine Antibody-Drug Conjugate.
Huang Y; Yuan J; Mu R; Kubiak RJ; Ball K; Cao M; Hussmann GP; de Mel N; Liu D; Roskos LK; Liang M; Rosenbaum AI
Antibodies (Basel); 2023 Oct; 12(4):. PubMed ID: 37873863
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Zeidan AM; DeAngelo DJ; Palmer J; Seet CS; Tallman MS; Wei X; Raymon H; Sriraman P; Kopytek S; Bewersdorf JP; Burgess MR; Hege K; Stock W
Ann Hematol; 2022 Mar; 101(3):557-569. PubMed ID: 34981142
[TBL] [Abstract][Full Text] [Related]
18. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P
Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412
[TBL] [Abstract][Full Text] [Related]
19. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.
Trudel S; Lendvai N; Popat R; Voorhees PM; Reeves B; Libby EN; Richardson PG; Anderson LD; Sutherland HJ; Yong K; Hoos A; Gorczyca MM; Lahiri S; He Z; Austin DJ; Opalinska JB; Cohen AD
Lancet Oncol; 2018 Dec; 19(12):1641-1653. PubMed ID: 30442502
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma.
Stewart AK; Krishnan AY; Singhal S; Boccia RV; Patel MR; Niesvizky R; Chanan-Khan AA; Ailawadhi S; Brumm J; Mundt KE; Hong K; McBride J; Shon-Nguyen Q; Xiao Y; Ramakrishnan V; Polson AG; Samineni D; Leipold D; Humke EW; McClellan JS; Berdeja JG
Blood Cancer J; 2019 Feb; 9(2):17. PubMed ID: 30718503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
